Development
SpringWorks Therapeutics, Inc.
SWTX
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -94.32M | -79.44M | -77.93M | -73.42M | -74.18M |
| Total Depreciation and Amortization | 538.00K | 494.00K | 382.00K | 253.00K | 255.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.38M | 24.56M | 24.33M | 24.96M | 19.89M |
| Change in Net Operating Assets | 3.70M | 3.92M | 5.41M | -13.61M | -167.00K |
| Cash from Operations | -62.71M | -50.46M | -47.81M | -61.82M | -54.20M |
| Capital Expenditure | 2.30M | -3.62M | -3.09M | -2.98M | -1.76M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -161.51M | 38.22M | 63.84M | 101.58M | -353.25M |
| Cash from Investing | -159.21M | 34.60M | 60.76M | 98.60M | -355.01M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 299.32M | 22.00K | 10.00K | 83.00K | 298.00K |
| Repurchase of Common Stock | -253.00K | -264.00K | -352.00K | -1.93M | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 299.07M | -242.00K | -342.00K | -1.85M | 298.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 77.16M | -16.10M | 12.60M | 34.94M | -408.91M |